Claudio Pinto

Dr. Claudio Pinto

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2018 in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Verified
Journal Article
Closed access
CPClaudio Pinto
Claudio Pinto
DGDebora Maria Giordano
Debora Maria Giordano
LMLuca Maroni
Luca Maroni
MMMarco Marzioni
Marco Marzioni

Verified
Journal Article
Open access
PDF file
DDebora maria Giordano
Debora maria Giordano
CPClaudio Pinto
Claudio Pinto
LMLuca Maroni
Luca Maroni
ABAntonio Benedetti
Antonio Benedetti
MMMarco Marzioni
Marco Marzioni
Cholangiocytes, the epithelial cells lining the bile ducts, represent the unique target of a group of progressive diseases known as cholangiopathies whose pathogenesis remain largely unknown. In normal conditions, cholangiocytes are quiescent and participate to the final bile volume and composition. Following exogenous or endogenous stimuli, cholangiocytes undergo extensive modifications of their phenotype. Reactive cholangiocytes actively proliferate and release a set of proinflammatory molecules, which act in autocrine/paracrine manner mediating the cross-talk with other liver cell types and innate and adaptive immune cells. Cholangiocytes themselves activate innate immune responses against gut-derived microorganisms or bacterial products that reach the liver via enterohepatic circulation. Gut microbiota has been implicated in the development and progression of the two most common cholangiopathies, i.e., primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), which have distinctive microbiota composition compared to healthy individuals. The impairment of intestinal barrier functions or gut dysbiosis expose cholangiocytes to an increasing amount of microorganisms and may exacerbate inflammatory responses thus leading to fibrotic remodeling of the organ. The present review focuses on the complex interactions between the activation of innate immune responses in reactive cholangiocytes, dysbiosis, and gut permeability to bacterial products in the pathogenesis of PSC and PBC.


17 March 2020 in Cells
Verified
Journal Article
Open access
PDF file
LMLuca Maroni
Luca Maroni
ENElisabetta Ninfole
Elisabetta Ninfole
CPClaudio Pinto
Claudio Pinto
ABAntonio Benedetti
Antonio Benedetti
MMMarco Marzioni
Marco Marzioni
The Nlrp3 inflammasome is a multiprotein complex activated by a number of bacterial products or danger signals and is involved in the regulation of inflammatory processes through caspase-1 activation. The Nlrp3 is expressed in immune cells but also in hepatocytes and cholangiocytes, where it appears to be involved in regulation of biliary damage, epithelial barrier integrity and development of fibrosis. Activation of the pathways of innate immunity is crucial in the pathophysiology of hepatobiliary diseases, given the strong link between the gut and the liver. The liver secretes bile acids, which influence the bacterial composition of the gut microbiota and, in turn, are heavily modified by microbial metabolism. Alterations of this balance, as for the development of dysbiosis, may deeply influence the composition of the bacterial products that reach the liver and are able to activate a number of intracellular pathways. This alteration may be particularly important in the pathogenesis of cholangiopathies and, in particular, of primary sclerosing cholangitis, given its strong association with inflammatory bowel disease. In the present review, we summarize current knowledge on the gut–liver axis in cholangiopathies and discuss the role of Nlrp3 inflammasome activation in cholestatic conditions.

18 December 2018 in Hepatology
Verified
Journal Article
Closed access
PDF file
LMLuca Maroni
Luca Maroni
CPClaudio Pinto
Claudio Pinto
DGDebora Maria Giordano
Debora Maria Giordano
SSStefania Saccomanno
Stefania Saccomanno
Jesús BañalesJesús Bañales
Jesús Bañales
MMMarco Marzioni
Marco Marzioni

1 April 2007 in Journal of Lipid Research
Verified
Journal Article
Open access
PDF file
AGArnaldo Gatica
Arnaldo Gatica
MAMauricio C. Aguilera
Mauricio C. Aguilera
DCDavid Contador
David Contador
GLGloria Loyola
Gloria Loyola
CPClaudio Pinto
Claudio Pinto
MBMiguel Bronfman
Miguel Bronfman
Peroxisomal proliferators, such as ciprofibrate, are used extensively as effective hypolipidemic drugs. The effects of these compounds on lipid metabolism require ligand binding activation of the peroxisome proliferator-activated receptor (PPAR) α subtype of nuclear receptors and involve transcriptional activation of the metabolic pathways involved in lipid oxidative metabolism, transport, and disposition. ω-Hydroxylated-eicosatrienoic acids (HEETs), products of the sequential metabolism of arachidonic acid (AA) by the cytochrome P450 CYP2C epoxygenase and CYP4A ω-hydroxylase gene subfamilies, have been identified as potent and high-affinity ligands of PPARα in vitro and as PPARα activators in transient transfection assays. Using isolated rat hepatocytes in culture, we demonstrate that specific inhibition of either the CYP2C epoxygenase or the CYP4A ω-hydroxylase abrogates ciprofibrate-induced peroxisomal proliferation, whereas inhibition of other eicosanoid-synthesizing pathways had no effect. Conversely, overexpression of the rat liver CYP2C11 epoxygenase leads to spontaneous peroxisomal proliferation, an effect that is reversed by a CYP inhibitor. Based on these results, we propose that HEETs may serve as endogenous PPARα ligands and that the P450 AA monooxygenases participate in ciprofibrate-induced peroxisomal proliferation and the activation of PPARα downstream targets.